Slideshows Archives - Oncology Nurse Advisor

Slideshows

Talimogene Laherparepvec (Imlygic)

  This slideshow reviews talimogene laherparepvec (Imlygic), indicated for unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery/ Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 26: Reference   

Belinostat (Beleodaq)

This slideshow reviews belinostat (Beleodaq), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). Table of Contents Slide 4: Dosage and AdministrationSlide 12: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 24: Reference 

Osimertinib (Tagrisso)

This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 22: What to Tell Your PatientSlide 29: Reference 

Palbociclib (Ibrance)

This slideshow reviews palbociclib (Ibrance), indicated for Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer . Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference 

Ceritinib (Zykadia)

This slideshow reviews ceritinib (Zykadia), indicated for metastatic non-small cell lung cancer (NSCLC) in patients with ALK-positive tumors. Table of Contents Slide 4: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 23: What to Tell Your PatientSlide 32: Reference   

Ruxolitinib (Jakafi)

This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea. Table of Contents Slide 4: Dosage and AdministrationSlide 17: Cautions, Effects, and InteractionsSlide 24: What to Tell Your PatientSlide 29: Reference

Acalabrutinib (Calquence)

  This slideshow reviews acalabrutinib (Calquence), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 17: What to Tell Your PatientSlide 23: Reference  

Decitabine (Dacogen)

This slideshow reviews decitabine (Dacogen), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 5: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference

Ibrutinib (Imbruvica)

  This slideshow reviews ibrutinib (Imbruvica), indicated for the treatment of certain leukemias and lymphomas and chronic graft versus host disease (cGVHD) in adult patients. Table of Contents Slide 5: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 24: What to Tell Your PatientSlide 32: Reference  

Next hm-slideshow in Slides